Dexcom's third-quarter revenue grew by 18% year-over-year to $769.6 million. The company launched G7 in five countries and expanded access to real-time CGM.
Revenue grew 18% versus the same quarter of the prior year to $769.6 million.
U.S. revenue growth of 17% and international revenue growth of 22%.
GAAP operating income of $147.5 million or 19.2% of revenue.
Initiated the international roll-out of Dexcom G7 with launches in the United Kingdom, Ireland, Germany, Austria, and Hong Kong.
The company is updating fiscal 2022 revenue and Non-GAAP Gross Profit Margin guidance, and reiterating guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin at the following levels:
Visualization of income flow from segment revenue to net income